智通财经APP讯，万邦医药(301520.SZ)发布公告，公司拟以自有资金或自筹资金3.02亿元收购安徽赛德盛医药科技有限公司(简称“赛德盛”)75.52%股权。交易完成后，赛德盛将成为公司控股子公司。
赛德盛成立于2010年，是专业的创新药临床试验外包服务商(CRO)，为全球医药企业和科研机构提供药物临床研究全流程一体化服务，具备临床试验全链条服务能力。此次交易有助于公司快速切入高景气的创新药临床研究领域，优化整体业务结构，深度契合医药行业长期发展趋势。公司将发挥平台优势，通过规范化治理、资源整合赋能标的公司，持续释放协同效应，增强核心竞争力与持续盈利能力，提升公司行业品牌影响力与长期投资价值。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.